Default welcome msg!

Library

Here you will find a list with links to all the articles available online and in our Library at Elemental.

Scientific Articles on Cannabis

Elemental Wellness Center
Updated 6-07-2016

Volume 5 (2016)
2016

Opioid and cannabinoid synergy in a mouse neuropathic pain model. Kazantzis, N P, et al.
British Journal of Pharmacology. 2016 June 9 (abstract).

Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. Patel, R R, et al.
Brain. 2016 June 5 (abstract).

Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. Wang, L L, et al.
European Journal of Pharmacology. 2016 June 3 786: 128-136 (abstract).

Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a case series. Trigo, J M, et al.
Journal of Addiction Medicine. 2016 June 3 (abstract).

Marijuana use and its effects in pregnancy. Chabarria, K C, et al.
American Journal of Obstetrics and Gynecology. June 2 (abstract).

Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. Zaurova, M, et al.
Journal of Medical Toxicology.2016 June 2 (abstract).

Associations between cannabis use and physical health problems in early midlife: a longitudinal comparison of persistent cannabis vs tobacco users. Meier, M H, et al.
JAMA Psychiatry. 2016 June 1 (abstract).

TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Elbaz, Mohamad, et al.
Oncotarget. 2016 May 27.

I use weed for my ADHD: a qualitative analysis of online forum discussions on cannabis use and ADHD. Mitchell, John T, et al.
PLOS ONE. 2016 May 26.

Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Andresen, S R, et al.
Pain. 2016 May 25 (abstract).

Marijuana use is not associated with progression to advanced liver fibrosis in HIV/HCV coinfected women. Kelly, E M, et al.
Clinical and Infectious Diseases. 2016 May 25 (abstract).

Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease. Manuel, I, et al.
Neuroscience. 2016 May 17 329: 284-293 (abstract).

Influence of previous failed antispasticity therapy on the efficacy and tolerability of THC:CBD oromucosal spray for multiple sclerosis spasticity. Haupts, M, et al.
European Neurology. 2016 May 10 75(5-6): 236-243 (abstract).

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Patti, F, et al.
Journal of Neurology Neurosurgery and Psychiatry. 2016 May 9.

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. López-Sendón Moreno, J L, et al.
Journal of Neurology. 2016 May 9 (abstract).

Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice. Yesilyurt, O, et al.
Archives of Dermatological Research. 2016 April 28 (abstract).

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Sonego, A B, et al.
Behavioural Brain Research. 2016 April 27 309: 22-28 (abstract).

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrheic skin and acne treatment. Oláh, A, et al.
Experimental Dermatology. 2016 April 20 (abstract).

No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO-HEPAVIH French cohort). Marcellin, F, et al.
Drug and Alcohol Review. 2016 April 13 (abstract).

Cannabidiol promotes browning in 3T3-L-1 adipocytes. Parray, H A, et al.
Molecular and Cellular Biochemistry. 2016 April 11 (abstract).

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Linge, R, et al.
Neuropharmacology. 2016 April 103: 16-26 (abstract).

1169-021 / 21-Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction. Poster presentation American College of Cardiology 2016 Scientific Sessions. 2016 April 3 (abstract).

Effects of fixed or self-titrated dosages of Savitex on cannabis withdrawal and cravings. Trigo, J M, et al.
Drug and Alcohol Dependence. 2016 April 1 161: 298-306 (abstract).

The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity. Marinelli, L, et al.
International Journal of Clinical Psychopharmacology. 2016 Mar.21 (abstract).

Cannabis and cancer: toward a new understanding. Ware, M A
Current Oncology. 2016 23 Suppl.2: S5-S6.

Why I chose to use cannabis. Perrier, L
Current Oncology. 2016 23 Suppl.2: S7.

Integrating cannabis into clinical cancer care. Abrams, D I
Current Oncology. 2016 23 Suppl.2: S8-S14.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Fischer, T, et al.
Current Oncology. 2016 23 Suppl.2: S15-S22.

Anticancer mechanisms of cannabinoids. Velasco, G, et al.
Current Oncology. 2016 23 Suppl.2: S23-32.

Use of cannabinoids in cancer care: palliative care. Aggarwal, S K
Current Oncology. 2016 23 Suppl. 2: S33-S36.

Medical cannabis associated with decreased opiate medication use in retrospective cross-sectional survey of chronic pain patients.. Boehnke, K F, et al.
Journal of Pain. 2016 Mar. 18 (abstract).

Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. Köfalvi, A, et al.
Neuropharmacology. 2016 Mar. 11 (abstract).

Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: commentary on and reanalysis of US National Survey on drug use in households data 2002-2011. Wall, M M, et al.
International Journal of Drug Policy. 2016 Mar. 29:9-13 (abstract).

Prohedonic effect of cannabidiol in a rat model of depression. Shoval, G, et al.
Neuropsychobiology. 2016 73(2): 123-129 (abstract).

Metabolic syndrome in people with a psychotic illness: is cannabis protective? Waterreus, A, et al.
Psychological Medicine. 2016 Mar.11: 1-12 (abstract).

Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats. Bakali, E, et al.
International Urogynecology Journal. 2016 Mar. 4 (abstract).

A single intrathecal or intraperitoneal injection of CB2 receptor agonist attenuates bone cancer pain and induces a time-dependent modifaction of GRK2. Lu, C, et al.
Cellular and Molecular Neurobiology. 2016 Mar.2 (abstract).

Combined treatment with morphine and ∆9-tetrahydrocannibinol (THC) in rhesus monkeys: antinociceptive tolerance and withdrawal. Gerak, L R, et al.
Journal of Pharmacology and Experimental Therapeutics. 2016 Mar. 2 (abstract).

An event-related potential study on the effects of cannabis on emotion processing. Troup, Lucy J, et al.
PLOS ONE. 2016 Feb. 29.

Use of cannabis during pregnancy and birth outcomes in an aboriginal birth cohort: a cross-sectional, population-based study. Brown, S J, et al.
BMJ Open. 2016 Feb. 23.

CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Tzadok, M, et al.
Seizure. 2016 Feb. 35: 41-44 (abstract).

Anti-inflammatory and osteoprotective effects of cannabinoid-2 receptor agonist Hu-308 in a rat model of lipopolysaccharide-induced periodontitis. Ossala, C A, et al.
Journal of Periodontology. 2016 Feb. 5:1-17 (abstract).

Adverse effects of cannabis on adolescent brain development: a longitudinal study. Camchong, J, et al.
Cerebral Cortex. 2016 Feb. 23 (abstract).

Health authorities data collection of THC:CBD (Sativex) oromucosal spray (L'Agenzia Italiana del farmaco web registry): figures after 1.5 years. Patti, Francesco
European Neurology. 2016 75(suppl.1): 9-12.

THC:CBD (Sativex) observational study data: evolution of resistant MS spasticity and associated symptoms. Trojano, Maria
European Neurology. 2016 75(suppl.1): 4-8.

THC:CBD (Sativex) in daily practice: available data from UK, Germany and Spain. Fernández, Oscar
European Neurology. 2016 75(suppl.1): 1-3.

Fatty acid amide hydrolase inhibitors anti-invasive and antimetastatic effects on lung cancer cells, Winkler, K, et al.
Oncotarget. 2016 Feb.22 (abstract).

Cannabis effects on driving longitudinal control with and without alcohol. Hartman, R L, et al.
Journal of Applied Toxicology. 2016 Feb. 18 (abstract).

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-y and CB2 pathways. Del Rio, C, et al.
Scientific Report. 2016 Feb.18 6:21703 (abstract).

Cannabis effects on driving longitudinal control with and without alcohol. Hartman, R L, et al.
Journal of Applied Toxicology. 2016 Feb.18 (abstract).

The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study. Haroutounian, S, et al.
Clinical Journal of Pain. 2016 Feb.17 (abstract).

Stimulation of cannabinoid CB1 receptors prevents nerve-mediated airway hyperreactivity in NGF-induced inflammation in mouse airways. Bozkurt, T E, et al.
European Journal of Pharmacology. 2016 Feb.16 (abstract).

Meta-analysis of the association between the level of cannabis use and risk of psychosis. Marconi, A, et al.
Schizophrinia Bulletin. 2016 Feb.15. (abstract).

Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Wilker, S, et al.
Psychoneuroendocrinology. 2016 Feb.12 67: 198-206 (abstract).

Cannabis and psychosis: a critical overview of the relationship. Ksir, C, et al.
Current Psychiatry Reports. 2016 Feb. 18(2): 12 (abstract).

A study of the impact of cannabis on doses of discharge antipsychotic medication in individuals with schizophrenia or schizoaffective disorder. Babatope, T, et al.
Psychiatric Quarterly. 2016 Feb.13 (abstract).

Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice. Frei, R B, et al.
Allergy. 2016 Feb. 6 (abstract).

Prior cannabis use is associated with outcome after intracerebral hemorrhage. Di Napoli, M, et al.
Cerebrovascular Diseases. 2016 Jan.29 41(5/6): 248-255 (abstract).

Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119). Helle, S, et al.
Schizophrenia Research. 2016 Jan. 170(1): 217-221 (abstract).

Prior cannabis use is associated with outcome after intracerebral hemorrhage. Di Napoli, M, et al.
Cerebrovascular Disease. 2016 Jan.29 41(5-6): 248-255 (abstract).

The cannabis sativa versus cannabis indica debate; an interview with Ethan Russo, MD. Piomelli, Danielle, et al.
Cannabis and Cannabinoid Research. 2016 1(1): 44-46.

Review on clinical studies with cannabis and cannabinoids 2010-2014. Kowal, Mikael A, et al.
Cannabinoids. 2016 11(special issue): 1-18.

Cannabis use, depression and anxiety: a 3-year prospective population-based study. Danielsson, Anna-Karin, et al.
Journal of Affective Disorders. 2016 193: 103-108.

Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model. Nam, Gaewon et al.
Annals of Dermatology. 2016 28(1): 22-29.

Medicinal Cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. Lanz, Christian et al.
PLOS ONE. 2016 January.

Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Jackson, N J, et al.
Proceedings of the National Academy of Sciences U S A. 2016 Jan. 19 (abstract).

Evaluating Sativex in neuropathic pain management; a clinical and neurophysiological assessment in multiple sclerosis.Russo, Margherita, et al.
Pain Medicine. 2016 January 13.

Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. Shelef, A, et al.
Journal of Alzheimers Disease. 2016 Jan.12 (abstract).

Effects of medical marijuana on migraine headache frequency in an adult population. Rhyne, D N, et al.
Pharmacotherapy. 2016 Jan. 9 (abstract).

Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Lee, W S, et al.
Molecular Medicine. 2016 Jan. 8 (abstract).

Volume 4 (2015)
2015

The association between cannabis use and anxiety disorders: results from a population-based representative sample. Feingold, D, et al.
European Neuropsychopharmacology. 2015 Dec. 29 (abstract).

Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Bianconi, F, et al.
Psycological Medicine. 2015 Dec. 16 1-9 (abstract).

Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy. Zoja, C, et al.
Nephron. 2015 Dec. 9 (abstract).

Pharmaceutical CBD (cannabidiol) shows promise for children with severe epilepsy. Significant seizure reduction in studies using CBD in combination with AEDs. American Epilepsy Society.
Science Daily. 2015 Dec.7.

Head and neck cancer among marijuana users; a meta-analysis of matched case-control studies. de Carvalho, M F. et al.
Archives of oral Biology. 2015 Dec. 60(12): 1750-1755 (abstract).

Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with ∆9-tetrahydrocannabinol. Cluny, Nina L, et al.
PLOS One 2015 December 3.

Long-term data of efficacy, safety and tolerability in a real life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. Paolicelli, D, et al.
Journal of clinical Pharmacology. 2015 Nov. 26 (abstract).

Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries. Shi, Yuyan, et al.
PLOS One 2015 November 25.

Controlled release tablet formulation containing natural 9 tetrahydrocannabinol. Punyamurthula, N S, et al.
Drug Development and Industrial Pharmacy. 2015 Nov. 20: 1-25 (abstract).

The effects of five day dosing with THCV in THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. Englund, A, et al.
Journal of Psychopharmacology. 2015 Nov. 17 (abstract).

Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. Sideli, L, et al.
Early Intervention in Psychiatry. 2015 Nov. 12 (abstract).

Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer's disease. Jayant, S, et al.
Pharmacological Biochemical Behavior. 2015 Nov. 11 (abstract).

Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. Hemachandra, D, et al.
Australian and New Zealand Journal of Public Health. 2015 Nov. 11 (abstract).

Cannabinoid receptor type 1 agonist ACEA improves recovery and protects neurons in ischemic stroke in mice. Caltana, L, et al.
Journal of Neurochemistry. 2015 Nov. 135(3): 616-629 (abstract).

Perinatal asphyxia results in altered expression of the hippocampal acylethanolamide/ endocannabinoid signaling system associated to memory impairments in postweaned rats. Blanco, Eduardo, et al.
Frontiers in Neuroanatomy. 2015 November 3.

Metabolic syndrome among marijuana users in the United States: an analysis of national health and nutrition examination survey data. Vidot, D C, et al.
American Journal of Medicine. 2015 Nov. 5 (abstract).

Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. Verty, A N A,
Plos One. 2015 November 20.

Substituting cannabis for prescription drugs, alcohol and other substance among medical cannabis patients: the impact of contextual factors. Lucas, Philippe, et al.
Drug and Alcohol Review. 2015 (abstract).

Cannabis species and cannabinoid concentration among sleep-disturbed medicinal cannabis users. Belendiuk, Katherine A, et al.
Addictive Behaviors. 2015 November 50: 176-181 (abstract).

Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Haney, M, et al.
Neuropsychopharmacology. 2015 Oct. 40(11): 2489-2498 (abstract).

A runner's high depends on cannabinoid receptors in mice. Fuss, J, et al.
Proceedings of the National Academy of Sciences USA. 2015 112(42): 13105-8 (absract).

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model arthritis. Hammell, D C, et al.
European Journal of Pain. 2015 Oct. 30 (absract).

Adult attention deficit hyperactivity symptoms and psychosis: epidemiological evidence from a population survey in England. Marwaha, S, et al.
Psychiatry Research. 2015 Sep.30, 229(1-2): 49-56 (abstract).

Relationship between cannabis and psychosis: reasons for use and associated clinical variables. Mané, A, et al.
Psychiatry Research. 2015 Sep.30, 229(1-2): 70-74 (abstract).

Cannabis for the management of pain: assessment of safety study (COMPASS). Ware, M A, et al.
Journal of Pain. 2015 Sep. 16 (see separate binder).

Association between marijuana use and adverse obstetrical and neonatal outcomes. Warshalk, C R, et al.
Journal of Perinatology. 2015 Sep.24 (abstract).

Cannabis. Grayson, Michelle.
Nature Supplement. 2015 September 24, 525 No. 750_supp ppS1-S18.

Actions of the dual FAAH/MAGL inhibitor JZL 195 in a murine neuropathic pain model. Adamson Barnes, N S, et al.
British Journal of Pharmacology. 2015 Sep. 23 (abstract).

Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Maguire, D R, et al.
Behavioural Pharmacology. 2015 Sep. 21 (abstract).

Neural correlates of cannabidiol and ∆9-tetrahydrocannabinol interactions in mice: implications for medical cannabis. Todd, S M, et al.
British journal of Pharmacology. 2015 Sep.17 (abstract).

Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Weiss, A, et al.
Drug and Alcohol Dependence. 2015 Sep.14 (abstract).

Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Lucas, P, et al.
Drug and Alcohol Review. 2015 Sep.14 (abstract).

Endocannabinoid modulation of predator stress-induced long-term anxiety in rats. Lim, J, et al.
Neuropsychopharmacology. 2015 Sep.11 (abstract).

Anadamide mediates cognitive judgement bias in rats. Kregiel, J, et al.
Neuropsychopharmacology. 2015 Sep. 9 (abstract).

The effect of medical marijuana laws on body weight. Sabia, Joseph J, et al.
Health Economics 2015 September 8.

Divergent marijuana trajectories among men: socioeconomic, relationship, and life satisfaction outcomes in the mid-30s. White, H R, et al.
Drug and Alcohol Dependence. 2015 Sep.5 (abstract).

Bone cell-autonomous contribution of type 2 cannabinoid receptor to breast cancer induced osteolysis. Sophocleous, Antonia, et al.
Journal of Biological Chemistry. 2015 Sep.4 290(36): 22049-60.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Bisaga, A, et al.
Drug and Alcohol Dependence. 2015 Sep.1 154: 38-45 (abstract).

The genetic structure of marijuana and hemp. Sawler, Jason, et al.
PLOS One. 2015 Aug. 26.

Pro-inflammatory obesity in aged cannabinoid-2 receptor-deficient mice. Schmitz, K, et al.
International Journal of Obesity. 2015 Aug. 25 (abstract).

Shared predisposition in the association between cannabis use and subcortical brain structure. Pagliaccio, David et al.
JAMA Psychiatry 2015 August 26.

Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. Ho, W S, et al.
British Journal of Pharmacology. 2015 Aug. 21 (abstract).

Sativex ® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. Leocani, L, et al.
Journal of Neurology. 2015 Aug. 20 (abstract).

Association between use of marijuana and male reproductive hormones and semen quality: a study among 1,215 healthy young men. Gundersen, T D, et al.
American of Epidemiology. 2015, 182(6): 473-481.

Endocannabinoid regulation of amyloid-induced neuroinflammation. Vàzquez, C, et al.
Neurobiology of Aging. 2015 Aug.15 (abstract).

Cannabidiol, a cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release. Gobira, P H, et al.
Neurotoxicology. 2015 Aug.15 (abstract).

Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide prospective, register-based study. Hjorthøj, C, et al.
Lancet Psychiatry. 2015 Aug. 12 (abstract).

Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis. Arnold, C, et al.
Schizophrenia Research. Aug. 7 (abstract).

Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Bechtold, J, et al.
Psychology of Addictive Behaviors. 2015 Aug. 3 (abstract).

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Mounsey, R B, et al.
Experimental Neurology. Aug. 2 273: 36-44 (abstract).

No additive effect of cannabis on cognition in schizophrenia. Power, B D, et al.
Schizophrenia Research. July 30 (abstract).

Brief report: cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples. Alshaarawy, O, et al.
Epidemiology. 2015 July 26 (4): 597-600 (abstract).

Natural outcome of cannabis use disorder: a three-year longitudinal follow-up. Feingold, D, et al.
Addiction. 2015 July 25 (abstract).

Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice. Gunduz, O, et al.
European Journal of Pain. 2015 July 24 (abstract).

Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases. Nettekoven, M, et al.
ChemMedChem. 2015 July 21 (abstract).

Notes from the field: death following ingestion of an edible marijuana product - Colorado, March 2014. Hancock-Allen, Jessica B, et al.
Morbidity and Mortality Weekly Report. 2015 July 24 64(28): 771-772.

Time-dependent protection of CB2 receptor agonist in stroke. Yu, Seong-Jin, et al.
PLOS One. 2015 July 17 10(7).

Activation of CB2 receptor is required for the therapeutic of ABHD6 inhibition in experimental autoimmune encephalomyelitis. Wen, J, et al.
Neuropharmacology. 2015 July 17 99: 196-209 (abstract).

Cannabis allergy: what do we know anno 2015. Decuyper, I, et al.
Archivum Immunologiae et Therapiae Experimentalis. 2015 July 16 (abstract).

Enhanced vasorelaxation of endogenous anandamide on thoracic aorta in renal vascular hypertension rats. Guo, Z, et al.
Clinical and Experimental Pharmacology and Physiology. 2015 July 14 (abstract).

Cannabinoids and terpenes as chemotaxonomic markers in cannabis. Elzinga, S, et al.
Natural Products Chemistry & Research. 2015 3(4): 181.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Bisaga, A, et al.
Drug and Alcohol Dependence. 2015 July 8 (abstract).

Nonsmoker exposure to secondhand cannabis smoke. III. Oral fluid and blood drug concentrations and corresponding subjective effects. Cone, E J, et al.
Journal of Analytical Toxicology. 2015 July 2 (abstract).

Cannabis use and reduced risk of insulin resistance analysis (ANRS CO13 HEPAVIH). Carrieri, Maria Patrizia et al.
Clinical Infectious Diseases. 2015 July 1 61.

Cannabis in cancer care. Abrams, Donald I, et al.
Clinical Pharmacology & Therapeutics. 2015 June 97(6): 575-586.

Medical marijuana for treatment of chronic pain and other medical and psychiatric problems. A clinical review.
Hill, Kevin P
JAMA. 2015 313 June 23/30 (24): 2474-2483.

Are cannabidiol and 9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. McPartland, John M, et al.
British Journal of Pharmacology. 2015 172: 737-753.

Cannabis sativa: the unconventional "weed" allergen. Ocampo, Thad L, et al.
Annals of Allergy, Asthma & Immunology. 2015 114: 187-92.

Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors. Shakoor, S, et al.
Psychiatry Research. 2015 June 30 227(2/3): 144-51 (abstract).

Cannabinoid dose and label accuracy in edible medical cannabis products. Vandrey, Ryan, et al.
JAMA. 2015 June 23/30 313(24): 2491-2493.

Medical marijuana. Is the cart before the horse. D'Souza, Deepak Cyril, et al.
JAMA. 2015 June 23/30 313(24): 2431-2432.

Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. Gilman, Jodi M, et al.
The Journal of Neuroscience. 2015 June 28 35(4): 1505-1512.

Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Stanley, C P, et al.
Cardiovascular Research. 2015 June 19 (abstract).

Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 1994: results from annual, repeated cross-sectional surveys. Hasin, Deborah S. et al.
The Lancet (psychiatry). 2015 June 16.

Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. Lynch, M E, et al.
Journal of Neuroimmune Pharmacology. 2015 June 10 (2): 293-301 (abstract).

Pharmacologic effects of cannabidiol on acute reperfused myocardial infarction in rabbits: evaluated with 3.OT cardiac magnetic resonance imaging and histopathology. Feng, Y, et al.
Journal of Cardiovascular Research. 2015 June 9 (abstract).

Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. van den Elsen, G A, et al.
Neurology. 2015 June 9 84(23): 2338-2346 (abstract).

Synergy between cannabidiol, cannabidiolic acid, and ∆9-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). Rock, E M, et al.
Behavioral Neuroscience. 2015 June 129 (3): 368-70 (abstract).

Cannabinoids for medical use: a systematic review and meta-analysis. Whiting, Penny F, et al.
JAMA. 2015 313(24): 2456-2473.

Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Hartman, Rebecca L, et al.
Clinical Chemistry. 2015 61(6): 850-869.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Presley, Chaela, et al.
Pharmacology, Research & Perspectives. 2015 3(4): 1-16.

Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been..... Baron, E P
Headache. 2015 May 25 (abstract).

Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Fu W, et al.
Neuroscience Letters. 2015 May 19 595:1-6 (abstract).

Cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples. Alshaarawy, O, et al.
Epidemiology. 2015 May 14 (abstract).

CB1 receptors modulate affective behaviour induced by neuropathic pain. Rácz, I, et al.
Brain Research Bulletin. 2015 May 114: 42-48 (abstract).

Use of prescription pain medications among medical cannabis patients: comparison of pain levels, functioning, and patterns of alcohol and other drug use. Perron, Brian E, et al.
Journal of Studies on Alcohol and Drugs. 2015 May 76(3): 406-418.

The antitumor activity of plant-derived non-psychoactive cannabinoids. McAllister, Sean D, et al.
Journal of Neuroimmune Pharmacology. 2015 April.

Differential role of cannabinoids in the pathogenesis of skin cancer. Glodde, N, et al.
Life Sciences. 2015 April 25 (abstract).

A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Felilú, A, at al.
British Journal of Pharmacology. 2015 April 8 (abstract).

Current status and future of cannabis research. Russo, Ethan B, et al.
Clinical Researcher. 2015 April 58.

Introduction to the endocannabinoid system. Russo, Ethan
Phytex Website. 2015.

Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in Colorado. Finseth, Taylor Andrew, et al.
Evidence Based Complementary and Alternative Medicine. 2015 article ID 874849.

Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder. Kvitland, Levi Roestad, et al.
BMC Psychiatry. 2015 15: 11.

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation In Parkinson's disease. Gòmez-Gálvez, Y, et al.
Progress in Neuropsychopharmacology & Biological Psychiatry. 2015 April 9 (abstract).

Efficacy of inhaled cannabis on painful diabetic neuropathy. Wallace, M S, et al.
Journal of Pain. 2015 April 2 (abstract).

Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Press, C A, et al. Epilepsy & Behavior. 2015 April 2 (abstract).

Medical marijuana for cancer. Kramer, Joan L.
CA A Cancer Journal for Clinicians. 2015 March/April 65(2): 109-122.

Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Bechtold, Jordan, et al.
Psychology of Addictive Behaviors. 2015 29(3): 552-563.

Overview of CBC Medicinal value of cannabinol (CBN)-Medical Marijuana Inc. 2015 Nov.11.

The disease-modifying effects of Savitex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to ∆(9)-tetrahydrocannabinol acting through CB1 receptors. Moreno-Martet, M, et al.
Multiple Sclerosis and Related Disorders. 2015 Nov. 4(6) 505-511 (abstract).

Overview of CBN. Medicinal value of cannabinol (CBN)-Medical Marijuana Inc. 2015 Oct.29.

No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk. Loflin, Mallory, et al.
Canadian Journal of Respiratory Therapy. 2015 51(1): 7-9.

Kluger, Benzi, et al.
Movement Disorders. 2015 30(3): 313-327.

Cannabidiol, a major non-psychotrophic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. Kogan, N M, et al.
Journal of Bone and Mineral Research. 2015 March 19 (abstract)

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Di Forti, Marta, et al.
The Lancet Psychiatry. 2015 March 2(3): 233-238.

Cannabis use in relation to obesity and insulin resistance in the Inuit population. Ngueta, Gerard et al.
Obesity. 2015 February 23(2).

Medical marijuana for digestive disorders: high time to prescribe? Gerich, Mark E, et al.
The American Journal of Gastroenterology. 2015 February 110: 208-214.

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Ahmed, Amir I A, et al.
Psychopharmacology. 2015 232: 2587-2595.

Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. van der Meer, F J, et al.
Psychological Medicine. 2015 Feb. 5:1-12 (abstract).

Cannabis use in relation to obesity and insulin resistance in the Inuit population. Ngueta, G, et al.
Obesity. 2015 Feb. 23 (2): 290-295 (abstract).

Selective nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. Morales, P, et al.
Journal of Medicinal Chemistry. 2015 Feb. 20 (abstract).

Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. Monteleone, A M, et al.
American Journal of Clinical Nutrition. 2015 Feb. 101(2): 262-269 (abstract).

Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Gallily, Ruth, et al.
Pharmacology & Pharmacy. 2015 Feb.10, 6: 75-85.

Association between cannabis use and the risk of bladder cancer: results from the California men's health study. Thomas, A A, et al.
Urology. 2015 Feb. 85(2): 388-393 (abstract).

Synthetic and natural cannabinoids: the cardiovascular risk. Russo, Ethan B
The British Journal of Cardiology. 2015 22(1) January-March: 7-9.

Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Lachenmeier, Dirk W, et al.
Scientific Reports. 2015 Jan. 30.

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Rahimi, A, et al.
Neuroscience. 2015 Jan.28: 290C: 279-287 (abstract).

Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. Weiland, Barbara, J, et al.
The Journal of Neuroscience. 2015 January 28 35(4): 1505-1512.

Proapoptotic effect of endocannabinoids in prostate cancer cells. Orellana-Serradell, O, et al.
Oncology Reports. 2015 Jan. 21.

Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. Feng, R, et al.
Molecular Carcinogenesis. 2015 Jan. 16 (abstract).

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Jetly, R, et al.
Psychoneuroendocrinology. 2015 Jan. 15, 51: 585-588 (abstract).

Two non-psychoactive cannabinoids reduce intra-cellular lipid levels and inhibit hepatosteatosis. Silvestri, C, et al.
Journal of Hepatology. 2015 Jan. 13 (abstract).

Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. de Campos, A C, et al.
Neuroscience. 2015 Jan. 13 (abstract).

Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: role of cyclooxcygenase-2 and novel J-series prostamides. Soliman, E, et al.
Molecular Carcinogenesis. 2015 Jan. 3 (abstract).

The conversation and transfer of cannabinoids from cannabis to smoke stream in cigarettes. Elzinga, Sytze, et al.
Natural Products and Chemistry Research. 2015 3 (1).

Volume 3 (2014-2013)
2014

Handbook of CannabisPertwee, Roger (ed.)
Oxford University Press. 2014 (see separate book).

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. Greco, Rosaria, et al.
The Journal of Headache and Pain. 2014, 15:14.

Activation of cannabinoid receptor 2 attenuates synovitis and joint destruction in collagen-induced arthritis. Gui, H, et al.
Immunobiology. 2014 Dec.30 (abstract).

Medical marijuana laws and suicides by gender and age. Anderson, DM, et al.
American Journal of Public Health. 2014 Dec. 104(12): 2369-2376 (abstract).

Elevated CB1 and GPR55 receptor expression in proximal tubule cells and whole kidney exposed to diabetic conditions. Jenkin, KA, et al.
Clinical and Experimental Pharmacology & Physiology. 2014 Dec.29 (abstract).

Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin (THCv) on food reward and aversion in healthy volunteers. Tudge, L, et al.
International Journal of Neuropsychopharmacology. 2014 Dec.25.

Involvement of central and peripheral receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain. Bagüés, A et al.
European Journal of Pharmacology. 2014 Dec.15, 745:69-75 (abstract).

Chronic Stimulation of the tone of endogenous anandamide reduces cue-and stress-induced relapse in rats. Chauvet, C, et al.
International Journal of Neuropsychopharmacology. 2014 Dec.5.

Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the pain and opioids in treatment (POINT) study. Degenhardt, L et al.
Drug Alcohol Dependence. 2014 Dec.10 (abstract).

Effects of marijuana exposure on expiratory airflow: a study of adults who participated in the U.S. national health and nutrition examination study. Kempker, JA, et al.
Annals of the American Thoracic Society. 2014 Dec.18 (abstract).

Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration. Silveira, JW, et al.
PLoS One. 2014 Dec.17 9(12).

The combination of cannabidiol and ∆9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Scott, Katherine A, et al.
Molecular Cancer Therapeutics. 2014 Dec.13 (12): 2955-67 (abstract).

Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury. Zhang, J, et al.
Journal of Cerebral Blood Flow & Metabolism. 2014 Dec. 10 (abstract).

Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Neelakantan, H, et al.
Behavioral Pharmacology. 2014 Dec.5 (abstract).

Gross morphological brain changes with chronic, heavy cannabis use. Lorenzetti, V, et al.
British Journal of Psychiatry. 2014 Nov. 27 (abstract).

∆9 Tetrahydrocannabinol attenuates staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells. Rao, R, et al.
British Journal of Pharmacology. 2014 Nov. 26 (abstract).

Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. Viana, TG, et al.
Psychopharmacology(Berl.). 2014 Nov.13 (abstract).

High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load recently infected people who use injection drugs. Milloy, MJ, et al.
Drug Alcohol Review. 2014 Nov. 11 (abstract).

Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Zhang, Hai-Ying et al.
Proceedings of the National Academy of Sciences. 2014 Nov.3 E5007-E5015.

Effect of marijuana use on outcomes in traumatic brain injury. Nguyen, B M, et al.
American Journal of Surgery. 2014 Oct. 80(10): 979-83 (abstract).

Legalization of medical marijuana and incidence of opioid mortality. Hayes, Marie J, et al.
JAMA Internal Medicine. 2014, 174(10): 1673-1674 (abstract).

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a cannabis-derived non-psychotropic cannabinoid. Borrelli, F, et al.
Carcinogenesis. 2014 Sep.30 (abstract).

Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Pietrzak, Robert H, et al.
Neuropsychopharmacoloy. 2014, 39:2519-2528 (abstract).

The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Tchantchou, F, et al.
Neuropharmacology. 2014, Oct. 85: 427-39 (abstract).

Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage. Smith, P H, et al.
Psychology of Addictive Behaviors. 2014 Sep, 28(3): 734-742 (abstract).

Cannabidiol improves vasorelaxation in Zucker Diabetic fatty rats through cyclooxygenase activation. Wheal, A J, et al.
Journal of Pharmacology and Experimental Therapeutics. 2014 Sep 11 (abstract).

Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability. Freidel, M, et al.
Acta Neurologica Scandinavica. 2014 Sep 11.

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. Bachhuber, M A, et al.
JAMA Internal Medicine. 2014 Aug 25 (abstract).

Preliminary, open-label, pilot study of add-on oral ∆9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Roitman, P, et al.
Clinical Drug Investigation. 2014 Aug, 34(8): 587-591 (abstract).

β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 mice through CB2 receptor activation and the PPARy pathway. Cheng, Y, et al.
Pharmacology. 2014 Aug, 94(1-2): 1-12 (abstract).

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Sexton, M, et al.
Inflammopharmacology. 2014 Oct, 22(5): 295-303 (abstract).

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. Aso, E, et al.
Journal of Alzheimers Disease. 2014, Aug 14 (abstract).

Cannabionoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Haustein, M, et al.
Biochemical Pharmacology. 2014 Jul 25, 15:92 (abstract).

The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Giordano, G N, et al.
Psychological Medicine. 2014 Jul 3: 1-8 (abstract).

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. Cameron, C, et al.
Journal of Clinical Psychopharmacology. 2014 Oct, 34(5): 559-564.

The impact of cannabis use on clinical outcomes in recent onset psychosis. Barrowclough, C, et al.
Schizophrenia Bulletin. 2014 July 9 (abstract).

Does the legalization of medical marijuana increase completed suicide? Rylander, M, et al.
The American Journal of Drug and Alcohol Abuse. 2014 Jul, 40(4): 269-273.

Type-1 cannabinoid receptor activity during Alzheimer's disease progression. Manuel, I, et al.
Journal of Alzheimers Disease. 2014 Jun 19, 42(3): 761-766 (abstract).

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. Waissengrin, B, et al.
Journal of Pain Symptom Management. 2014 Jun 14, pii: S0885-3924(14)00312-1 (abstract).

Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Flachenecker, P, et al.
European Neurology. 2014 Jun 18, 72(1-2): 95-102 (abstract).

Cannabis smoking and lung cancer risk: pooled analysis in the international lung cancer consortium. Zhang, L R, et al.
International Journal of Cancer. 2014 Jun 30.

Genetic predisposition to schizophrenia associated with increased use of cannabis. Power, R A, et al.
Molecular Psychiatry. 2014 Jun 24, EISSN: 1476-5578 (abstract).

β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Bahi, A, et al.
Physiology & Behavior. 2014 Jun 13, 135C: 119-124 (abstract).

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Chagas, M H, et al.
Journal of Clinical Pharmacy and Therapeutics. 2014 May 21, 2014 Oct, 39(5): 564-566 (abstract).

Cannabis and cannabinoids (PDQ). health professional version. National Cancer Institute. May 13 2014.

Δ9-Tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity. Castelli, Paola M, et al.
PLoS One. 2014: 9(5): e98079.

Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Buchy, L, et al.
Schizophrenia Research. 2014 May, 156(2-3): 277-280 (abstract).

Fasting and exercise increase plasma cannabinoid levels in THC pretreated rats: an examination of behavioural consequences. Wong, A, et al.
Psychopharmacology. 2014 Apr 3 (abstract).

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of parkinson disease: an open-label observational study. Lotan, I, et al.
Clinical Neuropharmacology. 2014 Mar-Apr, 37(2): 41-44 (abstract).

Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Rodriguez-Cueto, C, et al.
Pathobiology. 2014 Mar 14, 81(3): 49-159 (abstract).

Anandamide inhibits breast tumor-induced angiogenesis. Picardi, P, et al.
Translational Medicine. 2014, 10(3): 8-12.

Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use. Loflin, Mallory, et al.
Substance Use & Misuse. 2014 Mar, 49(4): 427-434 (abstract).

Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Lax, Pedro, et al.
Experimental Eye Research. 2014 Mar, 120: 175-185 (abstract).

Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1Δ E9 Mice. Cheng, D, et al.
Psychopharmacology. 2014 Aug, 231(15): 3009-3017 (abstract).

That which we call Indica, by any other name would smell as sweet. Erkelens, Jacob L, et al.
Cannabinoids. 2014, 9(1): 9-15.

Nabiximols (THC/CBD oromucosal spray, sativex in clinical practice-results of a multicenter, non-interventional study (move2) in patients with multiple sclerosis spasticity. Flachenecker, P, et al.
European Neurology. 201, 71(5-6): 271-279 (abstract).

Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Florek-Luszczki, Magdalena, et al.
Journal of Neural Transmission. 2014 Feb 19, 121(7): 707-715.

Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Schiavon, A P, et al.
Neurotoxicity Research. 2014 Feb 15 (abstract).

Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). Salaga, M, et al.
Journal of Chronic Colitis. 2014 Sep 1, 8(9): 998-1009.

Evaluation of selective of cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. Tambaro, S, et al.
European Journal of Pharmacology. 2014 Apr 15, 729: 67-74 (abstract).

Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors. Grassin-Delyle, S, et al.
British Journal of Pharmacology. 2014 Jun, 171(11): 2767-2777 (abstract).

Emerging clinical applications for cannabis and cannabinoids. A review of the recent scientific literature. Sixth
Edition.
Armentano, Paul.
The National Organization for the Reform of Marijuana Laws. Jan 13 2014: 1-69 (see separate binder).

Cannabidiol as a potential treatment for psychosis. Schubart, C D, et al.
European Neuropsychopharmacology. 2014 Jan, 24(1): 51-64 (abstract).

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson’s disease: an open-label observational study. Lotan, I, et al.
Clinical Neuropharmacology. 2014 Mar, 37(2): 41-44 (abstract).

Care and feeding of the endocannabinoid system: A systematic review of potential interventions that upregulate the endocannabinoid system. McPartland, John M, et al.
PLOS One. 2014 Mar, 9(3): 1-21.

The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Klauke, A L, et al.
European Neuropsychopharmacology. 2014 Apr, 24(4): 608-620 (abstract).

Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Harvey, B S, et al.
Cytokine. 2014 Feb, 65(2): 236-244 (abstract).

A controlled family study of cannabis users with and without psychosis. Proal, A C, et al.
Schizophrenia Research. 2014 Jan, 152(1): 283-288 (abstract).

Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Smith, S C, et al.
Neuro Endocrinology Letters. 2014 35(3): 198-201 (abstract).

Early phytocannabinoid chemistry to endocannabinoids and beyond. Mechoulam, Raphael et al.
Nature Reviews/Neuroscience 2014 Nov. 15: 757-764.

2013

Cannabis inflorescence, Cannabis spp. Standards of identity, analysis, and quality control. Upton, Roy, et al.
American Herbal Pharmacopoeia. 2013 Dec, (see separate binder).

Impact of ADHD and cannabis use on executive functioning in young adults. Tamm, Leanne, et al.
Drug and Alcohol Dependence. 2013 December 1 133(2).

Cannabidivarin (CBDV) suppresses penthylenetretrazole (PTZ)-induced increases in epilepsy-related gene expression. Amada, Naoki, et al.
Peer Journal. 2013 Nov 21, 1: e214.

Marijuana use patterns among patients with inflammatory bowel disease. Ravikoff Allegretti, Jessica, et al.
Inflammatory Bowel Diseases. 2013 Dec, 19(13): 2809-2814.

Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. Scott, K A, et al.
Anticancer Research. 2013 Oct, 33(10): 4373-4380 (abstract).

Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat. Calik, M W, et al.
Respiratory Physiology & Neurobiology. 2013 Oct, 190: 20-24.

Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes. Stanley, C P, et al.
European Journal of Pharmacology. 2013 Oct 8, 720(1-3): 376-382 (abstract).

Sub-types of attention deficit-hyperactivity disorder (ADHD) and cannabis use. Loflin, M, et al.
Substance Use & Misuse. 2013 Oct 4, 49(4): 427-434 (abstract).

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Ward, S J, et al.
British Journal of Pharmacology. 2014 Feb, 171(3): 636-645.

Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Cooper, Z D, et al.
Neuropsychopharmacology. 2013 Sep, 38(10): 1984-1992.

Why pot makes you feel good. Cholewa, K M, et al.
AlterNet.org. 2013 Aug 18, online article.

The endocannabinoid system and emotional processing: a pharmacological fMRI study with Δ9-tetrahydrocannabinol. Bossong, Matthijs G, et al.
European Neuropsychopharmacology. 2013 Dec, 23(12): 1687-1697.

The medicinal use of cannabis and cannabinoids - an international cross-sectional survey on administration forms. Hazekamp, A, et al.
Journal of Psychoactive Drugs. 2013 Jul-Aug, 45(3): 199-210 (abstract).

Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Brunet, Laurence, et al.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2013 Sep 1, 57(5): 663-670.

Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Morgan, C J, et al.
Addiction Behaviors. 2013 Sep, 38(9): 2433-2436 (abstract).

The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients supportive for palliative care. Bar-Sela, Gil, et al.
Evidence-based Complementary and Alternative Medicine. 2013, e510392.

An ultra-low dose of tetrahydrocannabinol provides cardioprotection. Waldman, M, et al.
Biochemical Pharmacology. 2013 Jun 1, 85(11): 1626-1633 (abstract).

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Wargent, E T, et al.
Nutrition and Diabetes. 2013 May 27, 3, e68.

Elevated brain cannabinoid CB1 receptor availability in posttraumatic stress disorder: a positron emission tomography study. Neumeister, Alexander, et al.
Molecular Psychiatry. 2013 Sep, 18(9): 1034-1040.

Talking terpenes. Lee, Martin, A
High Times. May 2013.

THC can prevent brain damage - study. Science 2.0, 2013 May 30.

Effects of marijuana smoking on the lung. Tashkin, Donald P
Annals of the American Thoracic Society. 2013 Jun, 10(3): 239-247.

Low-dose vaporized cannabis significantly improves neuropathic pain. Wilsey, B, et al.
Journal of Pain. 2013 Feb, 14(2): 136-148.

High on health: cannabinoids in the food supply. Badiner, Alan
www.wakingtimes.com. 2013 Apr 25.

Comparison of the analgesic effects of Dronabinol and smoked marijuana in daily marijuana smokers. Cooper, Z D, et al.
Neuropsychopharmacology. 2013 Sep, 38(10): 1984-1992.

Cannabinergic pain medicine: a concise primer and survey of randomized-controlled trial results. Aggarwal, S K
Clinical Journal of Pain. 2013, Feb 29(2): 162-171 (abstract).

Low dose vaporized cannabis significantly improves neuropathic pain. Wilsey, Barth, et al.
Journal of Pain. 2013 Feb 14(2): 136-148.

Information for health care professionals. Cannabis (marihuana, marijuana) and cannabinoids. Health Canada. February 2013 (see separate binder).

Marijuana: a primer. Armentano, Paul
NORML. 29 Jan 2013.

Risk of road-accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Elvik, R
Accident Analysis and Prevention. 2013 Nov. 60:254-267 (abstract).

Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Naftali, Timna, et al.
Clinical Gastroenterology and Hepatology. 2013 Oct, 11(10): 1276-1280 (abstract).

Role of cannabinoids in pain management. Russo, Ethan B, et al.
Comprehensive treatment of chronic pain by medical, interventional and integrative approaches. Deer, T.R., et al. (eds.), American Academy of Pain Medicine 2013 181-197.

Pregnancy, breast feeding, and marijuana: a review article. Hill, Meg, et al.
Obstetrical And Gynecological Survey. 2013 68(10): 710-718.

The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Penner, Elizabeth A, et al.
The American Journal of Medicine. 2013 126(7): 583-589.

Modulating the endocannabinoid system in human health and disease: successes and failures. Pacher, Pál, et al.
Federation of European Biochemical Societies (FEBS) Journal. 2013 280(9): 1918-1943.

Marijuana: current concepts. Greydanus, Donald E, et al.
Frontiers in Public Health 2013 October Article 42.

Volume 2 (2012-2010)
2012

Medical marijuana: clearing away the smoke. Grant, Igor, et al.
The Open Neurology Journal. 2012, 6: 18-25.

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Leweke, F M, et al.
Translational Psychiatry. 2012 2 e94.

Cannabis - a valuable drug that deserves better treatment. Mechoulam, Raphael
Mayo Clinic Proceedings. 2012 Feb, 87(2): 107-109.

Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Takeda, Shuso, et al.
Toxicol.Lett. 2012 Nov.15 214(3): 314-319.

Cannabinoid hyperemesis: a case series of 98 patients. Simonetto, D A, et al.
Mayo Clinic Proceedings. 2012 Feb, 87(2): 114-119.

Blurred boundaries: the therapeutics and politics of medical marijuana. Bostwick, Michael J
Mayo Clinic Proceedings. 2012 Feb, 87(2): 172-186.

Epigenetic regulation of fatty acid amide hydrolase in Alzheimer Disease. D'Addario, Claudio, et al.
PLoS One. 2012, 7(6): e39186.

Aroma therapy. Gardner, Fred
Medical Marijuana. 2012, 29-34.

Cannabidiol inhibits lung cancer cell invasion and metastasis. Ramer, Robert, et al.
The FASEB Journal, 2012 Apr, 1235-1248.

Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from cannabis sativa, on inflammation-induced hypermotility in mice. Izzo, Angelo, et al.
British Journal of Pharmacology. 2012 Jun, 166(4): 1444-1460.

Emerging clinical applications for cannabis and cannabinoids: a review of the recent scientific literature, 5th edition. Armento, Paul, et al.
NORML Foundation. 2012 Mar 14.

Cannabidivarin is anticonvulsant in mouse and rat. Hill, A J, et al.
British Journal of Pharmacology. 2012 Dec, 167(8): 1629-1642.

Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey(NHANES) III. Rajavashisth, Tripatith B, et al.
BMJ OPEN. 2012 2.

Naturally occurring anxiolytic substances from aromatic plants of genus citrus. Pimenta, Flavia Cristina Fernandes, et al.
Journal of Medicinal Plants Research. 2012 Jan 23, 6(3): 342-347.

The role of cannabinoids in prostate cancer: basic science perspective and potential clinical applications. Ramos, Juan A, et al.
Indian Journal of Urology. 2012 Jan, 28(1): 9-14.

Cannabidiol enhances anandamide signaling and alleviates psychotic symptomes of schizophrenia. Leweka, F M, et al.
Translational Psychiatry. 2012, e94.

2011

The endocannabinoid system and cancer: therapeutic implication. Guindon, Josee, et al.
British Journal of Pharmacology. 2011, 163: 1447-1467.

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Russo, Ethan B
British Journal of Pharmacology. 2011, 163: 1344-1364.

Sympto-relieving and neuroprotective effects of ten phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease. Garcia, C, et al.
British Journal of Pharmacology. 2011 Aug, 163(7): 1495-1506.

Obesity and cannabis use: results from 2 representative national surveys. Le Strat, Yann, et al.
American Journal of Epidemiology. 2011 Aug. 24.

Who are medical marijuana patients? Population characteristics from nine California assessment clinics. Reinarman, Craig, et al.
Journal of Psychoactive Drugs. 2011, 43(2): 128-135 (abstract).

Importance of terpenes. Spaulding, Nathan
Cannabishealthnewsmagazine.com. 2011 Nov 2013.

Booklets on cannabis and specific medical conditions. Americans for Safe Access (ASA). 2011 Feb.

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Lynch, Mary E, et al
British Journal of Pharmacology. 2011 72(5): 735-744.

2010

The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation pain in mice. Bolognini, Daniele, et al.
British Journal of Pharmacology. 2010 Jun, 160(3): 677-687.

Cannabinoids and the gut: New developments and emerging concepts. Izzo, Angelo A, et al.
Pharmacology & Therapeutics. 2010 126: 21-38 (abstract).

Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Morgan, Celia J A, et al.
Neuropsychopharmacology. 2010 Aug, 35(9): 1879-1885.

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Bhattacharyya, Sagnik, et al.
Neuropsychopharmacology. 2010 Feb, 35(3): 764-774.

Review on clinical studies with cannabis and cannabinoids 2005-2009. Hazekamp, Arno, et al.
Cannabinoids. 2010, 5 (special issue): 1-21.

Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Wolf, Susanna A, et al.
Cell Communication and Signaling. 2010, 8: 12 (abstract).

Cannabinoids and the gut: new developments and emerging concepts. Izzo, Angelo A, et al.
Pharmacology & Therapeutics. 2010, 126: 21-28.

Volume 1 (2010-1843)
2009

Cannabis Review. Hazekamp, Arno.
Department of Plant Metabolomics, Leiden University, Leiden. The Netherlands. 2008-2009.

Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Oesch, Susanne, et al.
Molecular Cancer Therapeutics. July 2009; 8(7): 1838-1845.

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). Fraser, G A.
CNS Neuroscience & Therapeutics. 2009 Winter, 15(1): 84-88 (abstract).

Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. Ren, Yanhua, et al.
The Journal of Neuroscience. 2009 Nov 25, 29(47): 14764-14769.

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Izzo, Angelo A, et al.
Trends in Pharmacological Sciences. 2009 30(10) (abstract).

A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Liang, C, et al.
Cancer Prevention Research (Phila). 2009 Aug, 2(8): 756-768 (abstract).

Preventative and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation. Rogerio, Alexandre P, et al.
British Journal of Pharmacology. 2009 Oct, 15(4): 1074-1087.

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). Fraser, G A
CNS Neuroscience and Therapeutics. 2009 Winter 15(1): 84-88 (abstract).

2008

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin. Pertwee, R G
British Journal of Pharmacology. 2008 Jan, 153(2): 199-215.

Cannabis improves symptoms of ADHD. Strohbeck-Kuehner, Peter, et al.
Cannabinoids. 2008, 3(1): 1-3.

Gut modulatory, blood pressure lowering, diuretic and sedative activities of cardamom. Gilani, Anwarul Hassan, et al.
Journal of Ethnopharmacology. 2008 Feb 12, 115(3): 463-472 (abstract).

Neuroprotective effects of cannabidiol in endotoxin-induced uvetis: critical role of p38 MAPK activation El-Remessy, A B, et al.
Molecular Vision. 2008, 14: 2190-2203.

Antihyperalgesic effect of a cannabis sativa in a rat model of neuropathic pain: mechanisms involved. Cormelli, F, et al.
Phytotherapeutic Research. 2008, 22(8): 1017-1024 (abstract).

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Zuardi, Antonio Waldo
Revista Brasileira de Psiquiatria. 2008, Sep, 30(3).

Cannabidiol, extracted from cannabis sativa selectively inhibits hypermotility in mice. Capasso, R, et al.
British Journal of Pharmacology. 2008 May 12, 154(5): 1001-1008.

A randomized, placebo-controlled, crossover trial cannabis cigarettes in neuropathic pain. Wilsey, B et al.
Journal of Pain. 2008, June 9(6): 506-521.

Cannabinoids in the management of difficult to treat pain. Russo, Ethan B
Therapeutics and Clinical Risk Management. 2008, 4(1): 245-259.

Influence on cannabis use on severity of hepatitis C disease. Ishida, Julie H, et al.
Clinical Gastroenterology and Hepatology. 2008 Jan, 6(1): 69-75.

2007

Marijuana cuts lung cancer tumor growth in half, study shows. American Association for Cancer Research
Sciencedaily.com. 2007 Apr 17.

Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have potential therapeutic values in the treatment of psoriasis. Wilkinson, J D, et al.
Journal of Dermatological Science. 2007 Feb, 45(2): 87-92 (abstract).

The effect of the volatile oil from ginger rhizomes (zingiber officinale), it’s fractions and isolated compounds on the 5-HT3 receptor complex and the serotoninergic system of the rat ileum. Rivazi, A, et al.
Planta Medica. 2007 Apr, 73(4): 355-362 (abstract).

Screening of antibacterial activities of twenty-one oxygenated monoterpenes. Kotan, Recep, et al.
Zeitschrift fur Naturforschung. 2007, 62c: 507-513 (abstract).

Sedative effect of monoterpene alcohols in mice: a preliminary screening. de Sousa, Damiao Pergentino, et al.
Zeitschrift fur Naturforschung. 2007, 62c: 563-566 (abstract).

D-Limonene: safety and clinical applications Sun, Jidong, et al.
Alternative Medicine Review. 2007, 12(3): 259-264.

Dosing medical marijuana: rational guidelines on trial in Washington State. Sunil, K, et al.
Medscape General Medicine. 2007, 9(3) 52.

2006

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Russo, Ethan, et al.
Medical Hypothesis. 2006, 66: 234-246.

Endocannabinoid mechanisms of pain modulation. Hohmann, Andrea G, et al.
The AAPS Journal. 2006 8(4): E693-E708.

A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis (cannador) for postoperative pain management. Holdcroft, Antita, et al.
Anesthesiology. 2006, 104(5): 1040-1046 (abstract).

Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Hazekamp, Arno, et al.
Journal of Pharmaceutical Sciences. 2006, 95(6): 1308-1317 (abstract).

Interaction between terpenes and penicillin on bacterial strains resistant to beta-lactam antibiotics. Gallucci, N, et al.
Molecular Medicinal Chemistry. 2006, 10: 30-32.

History of cannabis as a medicine: a review. Zuardi, Antonio Waldo
Revista Brasileira de Psiquiatria. 2006, 28(2): 153-157.

Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Zuardi, A W, et al.
Brazilian Journal of Medical and Biological Research. 2006, 39(4): 421-429.

Delta-9 tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Shmist, Y A, et al.
Molecular Cell Biochemistry. 2006 Feb. (abstract).

Antitumor activity of plant cannabinoids emphasis on the effect of cannabidiol on human breast carcinoma. Ligresti, Alessia, et al.
The Journal of Pharmacology and Experimental Therapeutics. 2006 318(3): 1375-1387.

Endocannabinoid mechanisms of pain modulation. Hohmann, Andrea G, et al.
The AAPS Journal. 2006 Nov. 17 8(4): E693-708.

2005

Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Thomas, Adele, et al.
British Journal of Pharmacology. 2005 Dec, 146(7): 917-926.

Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Salem, Mohammed Labib
International Immunopharmacology. 2005, 5: 1749-1770 (abstract).

Involvement of cannabinoids in cellular proliferation. Lopez-Rodriguez, Maria L, et al.
Mini-Reviews in Medicinal Chemistry. 2005, 5: 97-106 (abstract).

Antileishmanial activity of the terpene nerolidol. Arruda, Denise C, et al.
Antimicrobial Agents and Chemotherapy, 2005, 49(5): 1679-1687.

Chemical constituents of marijuana: the complex mixture of natural cannabinoids. ElSohly, Mahmoud A, et al.
Life Sciences. 2005 78: 539-548.

2004

Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Venderova, Katerina, et al.
Movement Disorders. 2004 Sep, 19(9): 1102-1106 (abstract).

Cannabis, cannabinoids and reproduction. Park, Boram, et al.
Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004, 70: 189-197.

Cannabis for dyskinesia in Parkinson’s disease. A randomized double-blind crossover study. Carroll, C B, et al.
Neurology. 2004 Oct 12, 63(7): 1245-1250 (abstract).

Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Avraham, Y, et al. Pharmacology Bioche
mistry and Behavior. 2004 Apr, 77(4): 675-684 (abstract).

Medicinal cannabis: rational guidelines for dosing. Carter, Gregory T, et al.
Drugs. 2004 May 7(5): 464-470.

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Russo, E B
Neuroendocrinology Letters. 2004 Feb-Apr, 25(1-2): 31-39 (abstract).

Chronic conditions treated with cannabis. Encountered between 1990-2004. “Dr. Tod’s List.” Mikuriya, Tod.
2004.

Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. Narishetty, Sunil Thomas Kumar, et al.
Journal of Controlled Release. 2004 Mar 24, 95(3): 367-379 (abstract).

2003

The therapeutic potential of cannabis. Baker, David, et al.
The Lancet Neurology. 2003 May, 2(5): 291-298 (abstract).

Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Grant, Igor, et al.
Journal of the International Neuropsychological Society. 2003 9: 679-689.

Cannabinoids and the gut. Vigna, Steven R,.
Gastroenterology. 2003 Sept. 125: 973-975 (editorial).

Possible endocannabinoid control of colorectal cancer growth. Ligresti, Alessia et al.
Gastroenterology. 2003 Sept. 125: 677-687.

Cannabis and ADD. Bearman, David
www.davidbearman.com. 2003.

Cannabis and the brain. Iversen, Leslie
Brain. 2003, 126: 1252-1270.

Guidelines for cultivating cannabis for medicinal purposes. Scholten, Willem K
Journal of Cannabis Therapeutics. 2003, 3(2): 51-61.

The inheritance of chemical phenotype in cannabis satival L. Meijer, Etienne P M de
Genetics. 2003 Jan 1, 163(1): 335-346.

An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Izzo, Angelo A, et al.
Gastroenterolology. 2003 Sept. 125: 765-774.

2002

A cDna clone for β-caryophyllene synthase from Artemisia annua. Cai, Yu, et al.
Phytochemistry. 2002 Nov, 61(5): 523-529 (abstract).

Chronic cannabis use in the compassionate investigational new drug program: an examination of benefits and adverse effects of legal cannabis. Russo, Ethan, et al.
Journal of Cannabis Therapeutics. 2002 2(1): 3-57.

2001

Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Kumar, R N, et al.
Anaesthesia. 2001 Nov, 56(11): 1059-1068 (abstract).

Cannabis and cannabis extracts: greater than the sum of their parts? McPartland, John, et al.
Hayworth Press. 2001.

2000 - 1843

Cannabinoids in clinical practice. Williamson, Elizabeth, et al.
Drugs. 2000 Dec, 60(6): 1303-1314 (abstract).

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Malfait, A M, et al.
Proceedings of the National Academy of Sciences. 2000, 97(17): 9561-9566.

Prevention and therapy of cancer by dietary monoterpenes. Crowell, Pamela L
Journal of Nutrition. 1999, 129(3): 775s-778s.

An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Ben-Shabat, Shimon, et al.
European Journal of Pharmacology. 1998 353: 23-31 (abstract).

Essential oil of cannabis sativa L. strains. Mediavilla, Vito, et al.
Journal of the International Hemp Association. 1997, 4(2): 82-85.

Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice. Yu, Suzanne G, et al.
Journal of Nutrition. 1995, 125(11): 2763-2767 (abstract).

Chemical ecology of cannabis. Pate, David W
Journal of the International Hemp Association. 1994, 2: 29, 32-37.

Action of cannabidiol on the anxiety and others effects produced by ∆9-thc in normal subjects. Zuardi, A W, et al.
Psychopharmacology. 1982 76: 245-250 (abstract).

Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Karler, Ralph
British Journal of Pharmacology. 1980 Mar, 68(3): 479-484.

On the preparation of the Indian hemp or gunjah. O’Shaughnessy, W B, et al.
Provincial Medical Journal. 1843, no. 123: 363-369.

live help software